Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Recurrence × Homoharringtonine × Clear all

Phase

Phase 3 2 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 2 Recurrence 1 Leukemia, Myeloid, Acute 1 Leukemia 1

Interventions

Cyclophosphamide 39 fludarabine 28 Dexamethasone 22 venetoclax 19 Cytarabine 16 Rituximab 13 pembrolizumab 12 fludarabine phosphate 12 Filgrastim 12 Gemcitabine 10 Etoposide 10 Granulocyte Colony-Stimulating Factor 9 carfilzomib 8 Vincristine 8 Topotecan 8 Lenalidomide 8 Interleukin-2 8 Decitabine 8 pomalidomide 7 Nivolumab 7 Melphalan 7 Everolimus 7 Doxorubicin 7 Calcium Dobesilate 7 Azacitidine 7 Vorinostat 6 Carboplatin 6 Bortezomib 6 obinutuzumab 5 ibrutinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04926285 2026-03-16

VEN-OM

University of Illinois at Chicago

Phase 1 Completed

Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡